Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab with Gemcitabine and Cisplatin in HER2-positive Biliary Tract Cancer
NCT03613168Phase 2Completed
- Start
- Jun 2019
- Primary completion
- Nov 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab in biliary tract cancer (BTC). Primary endpoint: Objective Response Rate at 6 months. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03613168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03613168.